

# Nathalie Goemans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4864852/publications.pdf>

Version: 2024-02-01

50  
papers

3,795  
citations

218677

26  
h-index

206112

48  
g-index

50  
all docs

50  
docs citations

50  
times ranked

3574  
citing authors

#	ARTICLE	IF	CITATIONS
1	Duchenne muscular dystrophy. <i>Nature Reviews Disease Primers</i> , 2021, 7, 13.	30.5	448
2	Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp>uchenne muscular dystrophy. <i>Annals of Neurology</i> , 2016, 79, 257-271.	5.3	428
3	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 1489-1498.	13.7	365
4	Ataluren treatment of patients with nonsense mutation dystrophinopathy. <i>Muscle and Nerve</i> , 2014, 50, 477-487.	2.2	357
5	Mutations of the Selenoprotein N Gene, Which Is Implicated in Rigid Spine Muscular Dystrophy, Cause the Classical Phenotype of Multiminicore Disease: Reassessing the Nosology of Early-Onset Myopathies. <i>American Journal of Human Genetics</i> , 2002, 71, 739-749.	6.2	326
6	Consensus Statement on Standard of Care for Congenital Muscular Dystrophies. <i>Journal of Child Neurology</i> , 2010, 25, 1559-1581.	1.4	200
7	Desmin-related myopathy with mallory body-like inclusions is caused by mutations of the selenoprotein N gene. <i>Annals of Neurology</i> , 2004, 55, 676-686.	5.3	178
8	Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. <i>Neuromuscular Disorders</i> , 2016, 26, 126-131.	0.6	142
9	A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2018, 28, 4-15.	0.6	102
10	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2022, 21, 42-52.	10.2	89
11	Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. <i>Lancet Neurology, The</i> , 2016, 15, 882-890.	10.2	77
12	European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. <i>European Journal of Paediatric Neurology</i> , 2020, 28, 38-43.	1.6	74
13	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. <i>PLoS ONE</i> , 2014, 9, e83400.	2.5	65
14	Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. <i>Neuromuscular Disorders</i> , 2013, 23, 618-623.	0.6	60
15	A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. <i>Neurology</i> , 2017, 89, 1811-1820.	1.1	58
16	Current Treatment and Management of Dystrophinopathies. <i>Current Treatment Options in Neurology</i> , 2014, 16, 287.	1.8	53
17	Renal function in children and adolescents with Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2015, 25, 381-387.	0.6	53
18	Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. <i>PLoS ONE</i> , 2016, 11, e0164684.	2.5	51

#	ARTICLE	IF	CITATIONS
19	Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOMI Trial. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 989-1001.	2.6	50
20	Six-Minute Walk Test: Reference Values and Prediction Equation in Healthy Boys Aged 5 to 12 Years. <i>PLoS ONE</i> , 2013, 8, e84120.	2.5	48
21	Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. <i>PLoS ONE</i> , 2019, 14, e0218683.	2.5	47
22	The clinical, histologic, and genotypic spectrum of <i>SEPN1</i> -related myopathy. <i>Neurology</i> , 2020, 95, e1512-e1527.	1.1	44
23	A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe. <i>Nucleic Acid Therapeutics</i> , 2019, 29, 13-15.	3.6	42
24	Clinical Variability in Spinal Muscular Atrophy Type III. <i>Annals of Neurology</i> , 2020, 88, 1109-1117.	5.3	34
25	Non-neural Muscle Weakness Has Limited Influence on Complexity of Motor Control during Gait. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 5.	2.0	33
26	Novel defects in collagen XII and VI expand the mixed myopathy/Ehlers-Danlos syndrome spectrum and lead to variant-specific alterations in the extracellular matrix. <i>Genetics in Medicine</i> , 2020, 22, 112-123.	2.4	33
27	Gait deviations in Duchenne muscular dystrophy—Part 1. A systematic review. <i>Gait and Posture</i> , 2018, 62, 247-261.	1.4	28
28	Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. <i>European Journal of Pediatrics</i> , 2019, 178, 253-258.	2.7	27
29	Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. <i>Neurology</i> , 2020, 95, e1381-e1391.	1.1	27
30	Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. <i>Neuromuscular Disorders</i> , 2020, 30, 756-764.	0.6	25
31	Gait deviations in Duchenne muscular dystrophy—Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy. <i>Gait and Posture</i> , 2018, 63, 159-164.	1.4	24
32	Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. <i>PLoS ONE</i> , 2020, 15, e0232870.	2.5	23
33	Test-retest reliability and developmental evolution of the 6-min walk test in Caucasian boys aged 5–12 years. <i>Neuromuscular Disorders</i> , 2013, 23, 19-24.	0.6	22
34	Gain and loss of abilities in type II SMA: A 12-month natural history study. <i>Neuromuscular Disorders</i> , 2020, 30, 765-771.	0.6	22
35	Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids. <i>Neuromuscular Disorders</i> , 2017, 27, 203-213.	0.6	19
36	Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes. <i>Translational Psychiatry</i> , 2019, 9, 200.	4.8	18

#	ARTICLE	IF	CITATIONS
37	Maternal copy-number variations in the DMD gene as secondary findings in noninvasive prenatal screening. <i>Genetics in Medicine</i> , 2019, 21, 2774-2780.	2.4	16
38	Human iPSC model reveals a central role for NOX4 and oxidative stress in Duchenne cardiomyopathy. <i>Stem Cell Reports</i> , 2022, 17, 352-368.	4.8	15
39	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. <i>Neuromuscular Disorders</i> , 2022, 32, 271-283.	0.6	13
40	Muscle weakness has a limited effect on motor control of gait in Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2020, 15, e0238445.	2.5	12
41	Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients. <i>Journal of Neuromuscular Diseases</i> , 2018, 5, 131-133.	2.6	10
42	How glucocorticoids change life in Duchenne muscular dystrophy. <i>Lancet, The</i> , 2018, 391, 406-407.	13.7	9
43	Normative data and percentile curves for the three-minute walk test and timed function tests in healthy Caucasian boys from 2.5 up to 6 years old. <i>Neuromuscular Disorders</i> , 2019, 29, 585-600.	0.6	9
44	Old measures and new scores in spinal muscular atrophy patients. <i>Muscle and Nerve</i> , 2015, 52, 435-437.	2.2	6
45	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. <i>PLoS ONE</i> , 2021, 16, e0253882.	2.5	6
46	Gene therapy for spinal muscular atrophy: hope and caution. <i>Lancet Neurology, The</i> , 2021, 20, 251-252.	10.2	5
47	Differences in Contraction-Induced Hemodynamics and Surface EMG in Duchenne Muscular Dystrophy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 876, 71-77.	1.6	1
48	Response to letter: A decision for life – Treatment decisions in newly diagnosed families with spinal muscular atrophy. <i>European Journal of Paediatric Neurology</i> , 2021, 30, 103-104.	1.6	1
49	The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2021, 31, 479-488.	0.6	0
50	Eteplirsen Delays Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy Compared With Patients Receiving Standard of Care. <i>Neuropediatrics</i> , 2019, 50, .	0.6	0